2025 Q4 -tulosraportti
3 päivää sitten
‧39 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 | NON | ENS | ||
| 150 | NON | ENS | ||
| 15 | NON | NON | ||
| 737 | DDB | ENS | ||
| 170 | DDB | ENS |
Ylin
16,65VWAP
Alin
15,8VaihtoMäärä
1,1 69 702
VWAP
Ylin
16,65Alin
15,8VaihtoMäärä
1,1 69 702
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·18 t sitten · Muokattu🔥 Is this a possible gamechanger for the entire case..?! 🔥 YES, it is..! – WOW!.............. Andreas Kjær is onto something big...!.......... It's going to be massive! ......It's going to be WILD..! ........yeahhh, there's nothing as good as Clickbait 😆🤣 ..... but there's something to it.... if they can show it (and they can, of course) There are others in this forum who have pondered the change from 6 pat. to 6-12 pat. in the annual report presentation, but the potential gamechanger lies in the other change also in the presentation - namely from 60 Gy to >100 Gy! The gain from >100 Gy (compared to 60 Gy) is not just a higher dose. It is nothing less than a qualitative change in the entire platform's position. It means: • stronger validation of uPAR as a therapeutic platform, • documentation of a real therapeutic window (high tumor dose without organ toxicity) • significantly better negotiating position with BP's • faster and more realistic transition to Phase II, • strengthened regulatory dialogue, • and potential international scientific recognition. The difference between 60 Gy and robust >100 Gy is therefore not linear. It is the difference between demonstrating that the technology works –and demonstrating that it can support a platform! Note, they have NOT moved the deadline for Phase I readout, H1 2026 Imagine they are changing a hyper-critical PoC study, which Phase I for uTREAT and thus the entire platform is! They could have played it safe with 60 Gy. Why,- because they can ! (and data for the first 5-6 pat, say that it is possible with a relatively low risk of failure). Andreas/ Ulrich, they are quite a pair of wild lads! ... uPAR Rock! Dive a little deeper into this... and remember, that DATA is King- we need to see it ! https://drive.google.com/file/d/1acGYRxkTpZg3DpWr-oXc7bT-3J_ujPAH/view?usp=drive_link ---------------------------------------------------------- ....and I still own all my shares (and a little), so this is not a recommendation to buy even more .....
·2 t sittenI assume you mean safe and not unsafe 😉 yes, I am also of the opinion that the longer time passes, i.e. months, the more expensive it will be to get on board for BIG PHARMA 😎
·2 päivää sittenI noted from yesterday's presentation that the phase 1 study in uTreat is now 6-12 patients. I believe the original trial design said 0-6 patients. Of course, they could end up with a number exactly at 6, but it otherwise seems like they are conducting a slightly larger trial, which, all things considered, seems to be on the positive side. Results also appear to be coming in June. It did not sound like management was less optimistic than before the trial started, when they were also optimistic.
·1 päivä sittenWhat I liked best about that presentation was Professor A. Kjær's concluding remark: Our optimism has not suffered a setback :) They are onto something big!
·3 t sittenAllanL. I was a shareholder in Intellego. There are some who bluff even though you don't think they can get anything out of it. But I don't think that's the case at all with Curasight. But just so you don't blindly trust boastful CEOs who cheat to send the stock price to the sky.
·2 päivää sittenSEB has, as I read it, still not included uTreat in their calculation model. So the enormous upside is missing if data in H1 are positive as we expect.
·1 päivä sittenIf one just had 30 million.....then they could quickly be out. But anyway....it doesn't bother me that the price is kept down, then hopefully more can be bought in before it takes off....
2 päivää sitten · Muokattu2 päivää sitten · MuokattuLinkedin opslag fra Ulrich CEO 17 timer siden: Pleased to share this recent BioStock article covering Curasight’s development in 2025 and our outlook for 2026. 2025 marked a pivotal transition for Curasight – from a predominantly diagnostic-focused company to a clinical-stage radioligand therapy developer. The dosing of the first patient in our Phase 1 glioblastoma trial with uTREAT® was a defining milestone and the beginning of active therapeutic clinical execution. At the same time, uTRACE® continued to validate uPAR biology in more than 450 patients across multiple solid tumour indications, and our ongoing Phase II prostate cancer study progressed across nine active sites in Europe. With a strengthened capital base and top-line data from the uTREAT GBM trial expected mid-2026, we look ahead to a catalyst-rich year that will help shape the next phase of our uPAR-targeted theranostic platform. Thank you to BioStock for the coverage – and to our team, partners, investigators and shareholders for the continued support. Kilde: LinkedIn https://share.google/k47H8lJwYxojAoOcLhttps://biostock.se/en/2026/02/curasights-2025-ett-ar-av-terapeutiska-framsteg-och-kliniska-framgangar/- ·2 päivää sittenSEB: 2026 could be an “inflection year” for Curasight The bank's new analysis indicates that the company is entering a crucial year with several important data-readouts: Preliminary efficacy data from glioblastoma (ph1/2) expected in Q2 2026 uTRACE prelim data expected in H1 2026 (topline H2 2026) First data from uTREAT also on the way SEB estimates that the company's cash (~36 mio. kr. by the end of 2025) is sufficient until these milestones. The point: Data-readouts in 2026 could become major “de-risking events” and thus crucial for the stock's direction. SEB maintains valuation: 14–36 kr. per share. https://research.sebgroup.com/corporate/reports/140253?fbclid=IwdGRleAQOMClleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeKXo0Hm4lfXu1R1xzxgETCic5-1Phuo3iDG7hb4WfSz-5daVI2PE_3GH5PiU_aem_1gm5ticfSS7wj6uu_ig5yQ·2 päivää sittenThey still don't have uTreat with the calculation, it's a bit strange, it will be exciting when it comes, expectedly after H1 data.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
3 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18 t sitten · Muokattu🔥 Is this a possible gamechanger for the entire case..?! 🔥 YES, it is..! – WOW!.............. Andreas Kjær is onto something big...!.......... It's going to be massive! ......It's going to be WILD..! ........yeahhh, there's nothing as good as Clickbait 😆🤣 ..... but there's something to it.... if they can show it (and they can, of course) There are others in this forum who have pondered the change from 6 pat. to 6-12 pat. in the annual report presentation, but the potential gamechanger lies in the other change also in the presentation - namely from 60 Gy to >100 Gy! The gain from >100 Gy (compared to 60 Gy) is not just a higher dose. It is nothing less than a qualitative change in the entire platform's position. It means: • stronger validation of uPAR as a therapeutic platform, • documentation of a real therapeutic window (high tumor dose without organ toxicity) • significantly better negotiating position with BP's • faster and more realistic transition to Phase II, • strengthened regulatory dialogue, • and potential international scientific recognition. The difference between 60 Gy and robust >100 Gy is therefore not linear. It is the difference between demonstrating that the technology works –and demonstrating that it can support a platform! Note, they have NOT moved the deadline for Phase I readout, H1 2026 Imagine they are changing a hyper-critical PoC study, which Phase I for uTREAT and thus the entire platform is! They could have played it safe with 60 Gy. Why,- because they can ! (and data for the first 5-6 pat, say that it is possible with a relatively low risk of failure). Andreas/ Ulrich, they are quite a pair of wild lads! ... uPAR Rock! Dive a little deeper into this... and remember, that DATA is King- we need to see it ! https://drive.google.com/file/d/1acGYRxkTpZg3DpWr-oXc7bT-3J_ujPAH/view?usp=drive_link ---------------------------------------------------------- ....and I still own all my shares (and a little), so this is not a recommendation to buy even more .....·2 t sittenI assume you mean safe and not unsafe 😉 yes, I am also of the opinion that the longer time passes, i.e. months, the more expensive it will be to get on board for BIG PHARMA 😎
- ·2 päivää sittenI noted from yesterday's presentation that the phase 1 study in uTreat is now 6-12 patients. I believe the original trial design said 0-6 patients. Of course, they could end up with a number exactly at 6, but it otherwise seems like they are conducting a slightly larger trial, which, all things considered, seems to be on the positive side. Results also appear to be coming in June. It did not sound like management was less optimistic than before the trial started, when they were also optimistic.·1 päivä sittenWhat I liked best about that presentation was Professor A. Kjær's concluding remark: Our optimism has not suffered a setback :) They are onto something big!·3 t sittenAllanL. I was a shareholder in Intellego. There are some who bluff even though you don't think they can get anything out of it. But I don't think that's the case at all with Curasight. But just so you don't blindly trust boastful CEOs who cheat to send the stock price to the sky.
- ·2 päivää sittenSEB has, as I read it, still not included uTreat in their calculation model. So the enormous upside is missing if data in H1 are positive as we expect.·1 päivä sittenIf one just had 30 million.....then they could quickly be out. But anyway....it doesn't bother me that the price is kept down, then hopefully more can be bought in before it takes off....
- 2 päivää sitten · Muokattu2 päivää sitten · MuokattuLinkedin opslag fra Ulrich CEO 17 timer siden: Pleased to share this recent BioStock article covering Curasight’s development in 2025 and our outlook for 2026. 2025 marked a pivotal transition for Curasight – from a predominantly diagnostic-focused company to a clinical-stage radioligand therapy developer. The dosing of the first patient in our Phase 1 glioblastoma trial with uTREAT® was a defining milestone and the beginning of active therapeutic clinical execution. At the same time, uTRACE® continued to validate uPAR biology in more than 450 patients across multiple solid tumour indications, and our ongoing Phase II prostate cancer study progressed across nine active sites in Europe. With a strengthened capital base and top-line data from the uTREAT GBM trial expected mid-2026, we look ahead to a catalyst-rich year that will help shape the next phase of our uPAR-targeted theranostic platform. Thank you to BioStock for the coverage – and to our team, partners, investigators and shareholders for the continued support. Kilde: LinkedIn https://share.google/k47H8lJwYxojAoOcLhttps://biostock.se/en/2026/02/curasights-2025-ett-ar-av-terapeutiska-framsteg-och-kliniska-framgangar/
- ·2 päivää sittenSEB: 2026 could be an “inflection year” for Curasight The bank's new analysis indicates that the company is entering a crucial year with several important data-readouts: Preliminary efficacy data from glioblastoma (ph1/2) expected in Q2 2026 uTRACE prelim data expected in H1 2026 (topline H2 2026) First data from uTREAT also on the way SEB estimates that the company's cash (~36 mio. kr. by the end of 2025) is sufficient until these milestones. The point: Data-readouts in 2026 could become major “de-risking events” and thus crucial for the stock's direction. SEB maintains valuation: 14–36 kr. per share. https://research.sebgroup.com/corporate/reports/140253?fbclid=IwdGRleAQOMClleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeKXo0Hm4lfXu1R1xzxgETCic5-1Phuo3iDG7hb4WfSz-5daVI2PE_3GH5PiU_aem_1gm5ticfSS7wj6uu_ig5yQ·2 päivää sittenThey still don't have uTreat with the calculation, it's a bit strange, it will be exciting when it comes, expectedly after H1 data.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 | NON | ENS | ||
| 150 | NON | ENS | ||
| 15 | NON | NON | ||
| 737 | DDB | ENS | ||
| 170 | DDB | ENS |
Ylin
16,65VWAP
Alin
15,8VaihtoMäärä
1,1 69 702
VWAP
Ylin
16,65Alin
15,8VaihtoMäärä
1,1 69 702
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
3 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·18 t sitten · Muokattu🔥 Is this a possible gamechanger for the entire case..?! 🔥 YES, it is..! – WOW!.............. Andreas Kjær is onto something big...!.......... It's going to be massive! ......It's going to be WILD..! ........yeahhh, there's nothing as good as Clickbait 😆🤣 ..... but there's something to it.... if they can show it (and they can, of course) There are others in this forum who have pondered the change from 6 pat. to 6-12 pat. in the annual report presentation, but the potential gamechanger lies in the other change also in the presentation - namely from 60 Gy to >100 Gy! The gain from >100 Gy (compared to 60 Gy) is not just a higher dose. It is nothing less than a qualitative change in the entire platform's position. It means: • stronger validation of uPAR as a therapeutic platform, • documentation of a real therapeutic window (high tumor dose without organ toxicity) • significantly better negotiating position with BP's • faster and more realistic transition to Phase II, • strengthened regulatory dialogue, • and potential international scientific recognition. The difference between 60 Gy and robust >100 Gy is therefore not linear. It is the difference between demonstrating that the technology works –and demonstrating that it can support a platform! Note, they have NOT moved the deadline for Phase I readout, H1 2026 Imagine they are changing a hyper-critical PoC study, which Phase I for uTREAT and thus the entire platform is! They could have played it safe with 60 Gy. Why,- because they can ! (and data for the first 5-6 pat, say that it is possible with a relatively low risk of failure). Andreas/ Ulrich, they are quite a pair of wild lads! ... uPAR Rock! Dive a little deeper into this... and remember, that DATA is King- we need to see it ! https://drive.google.com/file/d/1acGYRxkTpZg3DpWr-oXc7bT-3J_ujPAH/view?usp=drive_link ---------------------------------------------------------- ....and I still own all my shares (and a little), so this is not a recommendation to buy even more .....·2 t sittenI assume you mean safe and not unsafe 😉 yes, I am also of the opinion that the longer time passes, i.e. months, the more expensive it will be to get on board for BIG PHARMA 😎
- ·2 päivää sittenI noted from yesterday's presentation that the phase 1 study in uTreat is now 6-12 patients. I believe the original trial design said 0-6 patients. Of course, they could end up with a number exactly at 6, but it otherwise seems like they are conducting a slightly larger trial, which, all things considered, seems to be on the positive side. Results also appear to be coming in June. It did not sound like management was less optimistic than before the trial started, when they were also optimistic.·1 päivä sittenWhat I liked best about that presentation was Professor A. Kjær's concluding remark: Our optimism has not suffered a setback :) They are onto something big!·3 t sittenAllanL. I was a shareholder in Intellego. There are some who bluff even though you don't think they can get anything out of it. But I don't think that's the case at all with Curasight. But just so you don't blindly trust boastful CEOs who cheat to send the stock price to the sky.
- ·2 päivää sittenSEB has, as I read it, still not included uTreat in their calculation model. So the enormous upside is missing if data in H1 are positive as we expect.·1 päivä sittenIf one just had 30 million.....then they could quickly be out. But anyway....it doesn't bother me that the price is kept down, then hopefully more can be bought in before it takes off....
- 2 päivää sitten · Muokattu2 päivää sitten · MuokattuLinkedin opslag fra Ulrich CEO 17 timer siden: Pleased to share this recent BioStock article covering Curasight’s development in 2025 and our outlook for 2026. 2025 marked a pivotal transition for Curasight – from a predominantly diagnostic-focused company to a clinical-stage radioligand therapy developer. The dosing of the first patient in our Phase 1 glioblastoma trial with uTREAT® was a defining milestone and the beginning of active therapeutic clinical execution. At the same time, uTRACE® continued to validate uPAR biology in more than 450 patients across multiple solid tumour indications, and our ongoing Phase II prostate cancer study progressed across nine active sites in Europe. With a strengthened capital base and top-line data from the uTREAT GBM trial expected mid-2026, we look ahead to a catalyst-rich year that will help shape the next phase of our uPAR-targeted theranostic platform. Thank you to BioStock for the coverage – and to our team, partners, investigators and shareholders for the continued support. Kilde: LinkedIn https://share.google/k47H8lJwYxojAoOcLhttps://biostock.se/en/2026/02/curasights-2025-ett-ar-av-terapeutiska-framsteg-och-kliniska-framgangar/
- ·2 päivää sittenSEB: 2026 could be an “inflection year” for Curasight The bank's new analysis indicates that the company is entering a crucial year with several important data-readouts: Preliminary efficacy data from glioblastoma (ph1/2) expected in Q2 2026 uTRACE prelim data expected in H1 2026 (topline H2 2026) First data from uTREAT also on the way SEB estimates that the company's cash (~36 mio. kr. by the end of 2025) is sufficient until these milestones. The point: Data-readouts in 2026 could become major “de-risking events” and thus crucial for the stock's direction. SEB maintains valuation: 14–36 kr. per share. https://research.sebgroup.com/corporate/reports/140253?fbclid=IwdGRleAQOMClleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeKXo0Hm4lfXu1R1xzxgETCic5-1Phuo3iDG7hb4WfSz-5daVI2PE_3GH5PiU_aem_1gm5ticfSS7wj6uu_ig5yQ·2 päivää sittenThey still don't have uTreat with the calculation, it's a bit strange, it will be exciting when it comes, expectedly after H1 data.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 22 | NON | ENS | ||
| 150 | NON | ENS | ||
| 15 | NON | NON | ||
| 737 | DDB | ENS | ||
| 170 | DDB | ENS |
Ylin
16,65VWAP
Alin
15,8VaihtoMäärä
1,1 69 702
VWAP
Ylin
16,65Alin
15,8VaihtoMäärä
1,1 69 702
Välittäjätilasto
Dataa ei löytynyt